FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002891474> ?p ?o ?g. }

• W2002891474 endingPage "175" @default.
• W2002891474 startingPage "167" @default.
• W2002891474 abstract "Erythromelalgia is the main, pathognomonic and presenting symptom in patients with essential thrombocythemia and thrombocythemia associated with polycythemia vera. Complete relief from erythromelalgic and acrocyanotic pain is obtained with the cyclooxygenase inhibitors aspirin and indomethacin, but not with sodiumsalicylate, dipyridamol, sulfinpyrozone and ticlopedine. Thus, cyclooxygenase metabolites are necessary for erythromelalgia to develop. Local platelet consumption in erythromelalgic areas became evident by the demonstration of arteriolar fibromuscular intimal proliferation and occlusions by platelet-rich thrombi in skin biopsies, by the findings of shortened platelet survival times, significant higher levels of platelet activation markers beta-thromboglobulin, thrombomoduline and increased urinary thromboxane B2 excretion in thrombocythemia patients suffering from erythromelalgia. Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal. Erythromelalgia is frequently preceded or followed by atypical transient neurologic, ocular or coronary ischemic symptoms, which specifically respond to low-dose aspirin or reduction of platelet counts to normal. The broad spectrum of acropareshesias, erythromelalgia and acrocyanotic ischemia together with the episodic and transient atypical TIAs and ocular or coronary ischemic symptoms are caused by spontaneous activation and aggregation of hypersensitive platelets in the end-arterial microvasculature involving the peripheral, cerebral and coronary circulation of thrombocythemia patients. These microvascular circulation ischemic disturbances in thrombocythemia vera already occur at platelet counts in excess of 400 x 10(9) l(-1). Low-dose aspirin is highly effective and safe in the cure and prevention of thrombotic and ischemic events and does not elicit bleedings at platelet counts below 1000 x 10(9) l(-1). Spontaneous hemorrhages usually occur at very high platelet counts far in excess of 1000 x 10(9) l(-1) (HT) due to an acquired von Willebrand factor deficiency at increasing platelet counts. At platelet counts between 1000 and 2000 x 10(9) l(-1), thrombosis and bleeding (ETT and HT) frequently occur in sequence or paradoxically and low-dose aspirin does prevent thrombotic complications but aggravates or may elicit bleeding symptoms. Reduction of the platelet count to below 1000 x 10(9) l(-1) by platelet lowering agents usually results in the disappearance of the bleeding tendency and improvement of the von Willebrand syndrome, but the thrombotic tendency persists as long as platelet counts are above the upper limit of normal." @default.
• W2002891474 created "2016-06-24" @default.
• W2002891474 creator A5063661741 @default.
• W2002891474 date "2003-04-01" @default.
• W2002891474 modified "2023-09-29" @default.
• W2002891474 title "Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts" @default.
• W2002891474 cites W1493897517 @default.
• W2002891474 cites W1525465434 @default.
• W2002891474 cites W166660488 @default.
• W2002891474 cites W1902282150 @default.
• W2002891474 cites W194284594 @default.
• W2002891474 cites W1964592669 @default.
• W2002891474 cites W1987614225 @default.
• W2002891474 cites W1993371517 @default.
• W2002891474 cites W1998325169 @default.
• W2002891474 cites W2003400211 @default.
• W2002891474 cites W2005981464 @default.
• W2002891474 cites W2006973835 @default.
• W2002891474 cites W2016417342 @default.
• W2002891474 cites W2024028957 @default.
• W2002891474 cites W2033732447 @default.
• W2002891474 cites W2034792661 @default.
• W2002891474 cites W2038107955 @default.
• W2002891474 cites W2042115429 @default.
• W2002891474 cites W2043834061 @default.
• W2002891474 cites W2050334197 @default.
• W2002891474 cites W2051080180 @default.
• W2002891474 cites W2052421173 @default.
• W2002891474 cites W2068741393 @default.
• W2002891474 cites W2079118720 @default.
• W2002891474 cites W2079711150 @default.
• W2002891474 cites W2081665689 @default.
• W2002891474 cites W2081737706 @default.
• W2002891474 cites W2081918846 @default.
• W2002891474 cites W2084419568 @default.
• W2002891474 cites W2086419583 @default.
• W2002891474 cites W2086617296 @default.
• W2002891474 cites W2090664620 @default.
• W2002891474 cites W2102508274 @default.
• W2002891474 cites W2113957035 @default.
• W2002891474 cites W2121921061 @default.
• W2002891474 cites W2140972866 @default.
• W2002891474 cites W2142494158 @default.
• W2002891474 cites W2149377204 @default.
• W2002891474 cites W2162189197 @default.
• W2002891474 cites W2163261082 @default.
• W2002891474 cites W2229971338 @default.
• W2002891474 cites W2320032845 @default.
• W2002891474 cites W2334781899 @default.
• W2002891474 cites W3026101151 @default.
• W2002891474 doi "https://doi.org/10.1016/s0369-8114(03)00038-5" @default.
• W2002891474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12781799" @default.
• W2002891474 hasPublicationYear "2003" @default.
• W2002891474 type Work @default.
• W2002891474 sameAs 2002891474 @default.
• W2002891474 citedByCount "25" @default.
• W2002891474 countsByYear W20028914742012 @default.
• W2002891474 countsByYear W20028914742013 @default.
• W2002891474 countsByYear W20028914742015 @default.
• W2002891474 countsByYear W20028914742016 @default.
• W2002891474 countsByYear W20028914742017 @default.
• W2002891474 countsByYear W20028914742018 @default.
• W2002891474 countsByYear W20028914742020 @default.
• W2002891474 countsByYear W20028914742021 @default.
• W2002891474 countsByYear W20028914742022 @default.
• W2002891474 countsByYear W20028914742023 @default.
• W2002891474 crossrefType "journal-article" @default.
• W2002891474 hasAuthorship W2002891474A5063661741 @default.
• W2002891474 hasConcept C126322002 @default.
• W2002891474 hasConcept C164705383 @default.
• W2002891474 hasConcept C2776625714 @default.
• W2002891474 hasConcept C2777628954 @default.
• W2002891474 hasConcept C2778837598 @default.
• W2002891474 hasConcept C2779788118 @default.
• W2002891474 hasConcept C2780868729 @default.
• W2002891474 hasConcept C2781057849 @default.
• W2002891474 hasConcept C3018697912 @default.
• W2002891474 hasConcept C42219234 @default.
• W2002891474 hasConcept C71924100 @default.
• W2002891474 hasConcept C89560881 @default.
• W2002891474 hasConcept C90924648 @default.
• W2002891474 hasConceptScore W2002891474C126322002 @default.
• W2002891474 hasConceptScore W2002891474C164705383 @default.
• W2002891474 hasConceptScore W2002891474C2776625714 @default.
• W2002891474 hasConceptScore W2002891474C2777628954 @default.
• W2002891474 hasConceptScore W2002891474C2778837598 @default.
• W2002891474 hasConceptScore W2002891474C2779788118 @default.
• W2002891474 hasConceptScore W2002891474C2780868729 @default.
• W2002891474 hasConceptScore W2002891474C2781057849 @default.
• W2002891474 hasConceptScore W2002891474C3018697912 @default.
• W2002891474 hasConceptScore W2002891474C42219234 @default.
• W2002891474 hasConceptScore W2002891474C71924100 @default.
• W2002891474 hasConceptScore W2002891474C89560881 @default.
• W2002891474 hasConceptScore W2002891474C90924648 @default.
• W2002891474 hasIssue "3" @default.
• W2002891474 hasLocation W20028914741 @default.
• W2002891474 hasLocation W20028914742 @default.
• W2002891474 hasOpenAccess W2002891474 @default.

• next